Korean Circ J.  2014 May;44(3):200-202. 10.4070/kcj.2014.44.3.200.

Statins for Patients with Cardiogenic Shock

• Champion S

• KMID: 2145484
• DOI: http://doi.org/10.4070/kcj.2014.44.3.200

Abstract

No abstract available.

MeSH Terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Shock, Cardiogenic*

Reference

1. Sim DS, Jeong MH, Cho KH, et al. Effect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarction. Korean Circ J. 2013; 43:100–109.

2. Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J. 2010; 31:1828–1835.

3. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009; 119:1211–1219.

4. Champion S, Gaüzère BA, Vandroux D. Hypophosphatemia in patients with cardiogenic shock. J Crit Care. 2012; 27:511.

5. Champion S, Gaüzère BA, Lefor Y. Drug-eluting stents should not be used in ST-elevated myocardial infarction with cardiogenic shock. Arch Intern Med. 2012; 172:1613–1614.

6. Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One. 2011; 6:e28124.

7. Koreny M, Karth GD, Geppert A, et al. Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med. 2002; 112:115–119.